Literature DB >> 26595307

The prognostic value of p53 expression for patients with cervical cancer: a meta analysis.

Ruoyu Zhou1, Chuanyu Wei1, Jing Liu1, Ying Luo1, Wenru Tang2.   

Abstract

OBJECTIVE: A number of studies have evaluated the association of p53 expression with the cervical cancer clinical outcome, but the results were inconsistent. STUDY
DESIGN: Electronic search of PubMed was conducted to select studies. Studies which quantitatively evaluated the relationship between p53 expression and survival of the patients with cervical cancer were chosen, and hazard ratio (HR) with 95% confidence interval (CI) was used to assess the association.
RESULTS: The final meta-analysis contained 11 published studies including 1105 patients. Combined HRs suggested that p53 overexpression has an unfavorable impact on overall survival(OS) [HR=1.672, 95% confidence interval (CI): 1.144-2.444, P=0.008], and Caucasian cervical cancer patients OS[HR=1.942, 95% CI: 1.162-3.245, P=0.011].
CONCLUSIONS: p53 expression indicates a poor prognosis for Caucasian people with cervical cancer.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Expression; Meta-analysis; Prognosis; p53

Mesh:

Substances:

Year:  2015        PMID: 26595307     DOI: 10.1016/j.ejogrb.2015.10.006

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.831


  8 in total

Review 1.  State of Art of Cancer Pharmacogenomics in Latin American Populations.

Authors:  Andrés López-Cortés; Santiago Guerrero; María Ana Redal; Angel Tito Alvarado; Luis Abel Quiñones
Journal:  Int J Mol Sci       Date:  2017-05-23       Impact factor: 5.923

2.  MiR-142 inhibits the development of cervical cancer by targeting HMGB1.

Authors:  Daqiong Jiang; Huiyan Wang; Zhuyan Li; Zhen Li; Xin Chen; Hongbing Cai
Journal:  Oncotarget       Date:  2017-01-17

3.  Securidaca-saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells.

Authors:  Titus Chukwuemeka Obasi; Cornelia Braicu; Bogdan Cezar Iacob; Ede Bodoki; Ancuta Jurj; Lajos Raduly; Ilioara Oniga; Ioana Berindan-Neagoe; Radu Oprean
Journal:  Cancer Manag Res       Date:  2018-11-15       Impact factor: 3.989

4.  Screening and Discovery of New Potential Biomarkers and Small Molecule Drugs for Cervical Cancer: A Bioinformatics Analysis.

Authors:  Hui-Zhu Qiu; Ji Huang; Cheng-Cheng Xiang; Rong Li; Er-Dong Zuo; Yuan Zhang; Li Shan; Xu Cheng
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

5.  Elevated serum expression of p53 and association of TP53 codon 72 polymorphisms with risk of cervical cancer in Bangladeshi women.

Authors:  Md Shaki Mostaid; Sadia Biswas Mumu; Md Aminul Haque; Shahana Sharmin; Mohd Raeed Jamiruddin; Ghazi Muhammad Sayedur Rahman; Hasan Mahmud Reza
Journal:  PLoS One       Date:  2021-12-28       Impact factor: 3.240

6.  ROC-Analysis Derived Immunohistochemical P53 Cut-Off Scores as an Adjunct to Routine Histopathology for Better Diagnostic Compartmentalisation of Cervical Lesions.

Authors:  Ayushi Shukla; Rekha Sachan; Malti Maurya; Munna Lal Patel; Pushplata Sankhwar
Journal:  Int J Appl Basic Med Res       Date:  2022-07-26

7.  Nuclear Expression of GS28 Protein: A Novel Biomarker that Predicts Worse Prognosis in Cervical Cancers.

Authors:  Uiju Cho; Hae-Mi Kim; Hong Sik Park; Oh-Joo Kwon; Ahwon Lee; Seong-Whan Jeong
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

8.  TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer.

Authors:  Ikumi Kuno; Daisuke Takayanagi; Yuka Asami; Naoya Murakami; Maiko Matsuda; Yoko Shimada; Sou Hirose; Mayumi Kobayashi Kato; Masaaki Komatsu; Ryuji Hamamoto; Kae Okuma; Takashi Kohno; Jun Itami; Hiroshi Yoshida; Kouya Shiraishi; Tomoyasu Kato
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.